We recorded 114 VC/PE transactions pertaining to the global life sciences sector for June 2021, aggregating to a sum of USD 6.47B. The USA recorded 69 transactions aggregating to a total investment of USD 3.26B. China reported investment of USD 886m from 11 VC/PE transactions. Rest of the world accounted…
Read More
FY21 didn’t turn out too bad for CL Educate. In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. That is not to say it was a rosy FY21 for CL. The global scourge Covid…
Read More
Chemcrux Enterprises suffered only a 7% revenue drop and 17% EBITDA drop in FY21, despite losing over 23% of productive days due to plant closure, and Covid related production constraints in FY21. Highlights of the FY21 results: FY21 full year sales came in at Rs 533m, 7% drop over sales…
Read More We recorded 94 VC/PE transactions pertaining to the global life sciences sector for May 2021, aggregating to a sum of USD 6.56B. The USA recorded 60 transactions aggregating to a total investment of USD 3.3B. China reported investment of USD 1.8B from 12 VC/PE transactions. Rest of the world accounted…
Read More We recorded 131 VC/PE transactions pertaining to the global life sciences sector for April 2021, aggregating to a sum of USD 6.5B. The USA recorded 88 transactions with total investment of USD 3.8B. China reported investment of USD 585m from 12 VC/PE transactions. Rest of world accounted for 31 transactions…
Read More We recorded 130 VC/PE transactions pertaining to the global life sciences sector for March 2021, aggregating to a sum of USD 9.2B. This is an all-time high deal count as well as amount. The USA recorded 86 transactions with total investment of USD 6.3B. China reported investment of USD 1.7B…
Read More Covid and FY21 proved to be a blessing in disguise for digital businesses. CL Educate has reaped the rewards for being Digital ready well before the start of the Covid phase. In FY20, CL Educate was deep into its digital drive in both its key businesses – Education (Career Launcher)…
Read More
BeiGene’s outlicensing deal with Novartis underscores how Chinese pharma companies are yards ahead of Indian pharma companies now. Novartis, the Swiss Big Pharma company, has agreed to pay BeiGene $650 million upfront and up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales. This is in exchange…
Read More Founded in 2019, EQRx has closed 2 massive rounds in under 13 months. It first raised a Series-A round of USD200m in Jan’20 as part of its launch. Then in Jan’21, it has again shaken up the pharma world with a USD500m Series-B EQRx is targeting Equivalar medicines EQRx’ stated…
Read More We recorded 114 venture capital / private equity (VC/PE) transactions pertaining to the global life sciences sector for January 2021, aggregating to a sum of USD 6.275B. USA recorded 64 transactions for with total investment of USD 4B. China reported investment of USD 1B over 15 VC/PE transactions. India saw…
Read More